AbbVie Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 4/6

AbbVie şu anki getirisi 3.71% olan temettü ödeyen bir şirkettir. Bir sonraki ödeme tarihi olan 14th February, 2025 temettüden önceki tarihi 15th January, 2025 dir.

Anahtar bilgiler

3.7%

Temettü verimi

0.4%

Geri Alım Getirisi

Toplam Hissedar Getirisi	4.1%
Gelecekteki Temettü Verimi	3.9%
Temettü Büyümesi	1.3%
Bir sonraki temettü ödeme tarihi	14 Feb 25
Eski temettü tarihi	15 Jan 25
Hisse başına temettü	€6.560
Ödeme oranı	216%

Son temettü ve geri alım güncellemeleri

Recent updates

Yaklaşan Temettü Ödemesi

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: ABBV şirketinin hisse başına düşen temettüsü son 10 yıldır istikrarlıydı.

Büyüyen Temettü: ABBV şirketinin temettü ödemeleri son 10 yıldır artış göstermektedir.

Piyasaya Karşı Temettü Getirisi

AbbVie Piyasaya Karşı Temettü Getirisi

ABBV temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (ABBV)	3.7%
Pazarın Alt %25'i (AT)	2.1%
Pazarın En İyi %25'i (AT)	6.2%
Sektör Ortalaması (Biotechs)	1.6%
Analist tahmini (ABBV) (3 yıla kadar)	3.9%

Önemli Temettü: ABBV 'in temettüsü ( 3.71% ), Austrian piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 2.09% ) daha yüksektir.

Yüksek Temettü: ABBV 'in temettüsü ( 3.71% ), Austrian piyasasındaki temettü ödeyenlerin en üst %25'ine ( 6.2% ) kıyasla düşüktür.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Yüksek ödeme oranı ( 215.8% ) nedeniyle ABBV 'un temettü ödemeleri kazançlar tarafından yeterince karşılanmıyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Makul nakit ödeme oranı ( 74.2% ) ile ABBV 'un temettü ödemeleri nakit akışları ile karşılanmaktadır.

AbbVie Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 4/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on February 14, 2025

Upcoming dividend of US$1.55 per share

Upcoming dividend of US$1.55 per share

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024

Upcoming dividend of US$1.55 per share

Recent updates

New minor risk - Share price stability

Abbvie Receives European Commission Approval of Elahere (Mirvetuximab Soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer

Third quarter dividend of US$1.64 announced

Investor sentiment deteriorates as stock falls 16%

AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on February 14, 2025

Third quarter 2024 earnings released: EPS: US$0.88 (vs US$1.00 in 3Q 2023)

AbbVie Inc. (NYSE:ABBV) entered into an agreement to acquire Aliada Therapeutics, Inc. for $1.4 billion.

U.S. FDA Approves AbbVie (Foscarbidopa and Foslevodopa) for Adults Living with Advanced Parkinson's Disease

Upcoming dividend of US$1.55 per share

Allergan Aesthetics Announces Availability of Juvederm Voluma Xc for Moderate to Severe Temple Hollowing

AbbVie Inc. to Report Q3, 2024 Results on Oct 30, 2024

Abbvie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

Second quarter dividend of US$1.55 announced

AbbVie's VrayLAR®? (Cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia

Abbvie Receives Second Indication Approval from European Commission for Tepkinly® (Epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

AbbVie Inc. Announces Ontario and Quebec Are First Provinces to Reimburse Subcutaneous Epkinly™ (Epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process

Executive Chairman recently sold €11m worth of stock

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) from FMR LLC and others.

New minor risk - Profit margin trend

Second quarter 2024 earnings released: EPS: US$0.77 (vs US$1.14 in 2Q 2023)

AbbVie Inc. Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie's EPKINLY™ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency

Abbvie Announces Appointment of Roopal Thakkar as Executive Vice President, Research & Development and Chief Scientific Officer

Upcoming dividend of US$1.55 per share

AbbVie Inc. to Report Q2, 2024 Results on Jul 25, 2024

AbbVie Announces Board Changes

AbbVie Receives Positive CHMP Opinion for Epcoritamab (Tepkinly) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma

AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)

First quarter dividend of US$1.55 announced

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024

AbbVie Inc. Announces Board of Directors Changes

AbbVie Inc. Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRa) Expressing Platinum-Sensitive Ovarian Cancer

AbbVie Advances Oncology Pipeline with Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Landos Biopharma, Inc. (NasdaqCM:LABP) from a group of shareholders.

Health Canada Approves QULIPTA (atogepant) for the Preventive Treatment of Chronic Migraine in Adults

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

First quarter 2024 earnings released: EPS: US$0.77 (vs US$0.13 in 1Q 2023)

AbbVie Inc. Announces Positive Topline Results from Level Up

AbbVie Announces Positive Top-Line Results from SELECT-GCA Study of Upadacitinib (RINVOQ) Showed Positive Results in Patients with Giant Cell Arteritis

AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine

Upcoming dividend of US$1.55 per share

Yaklaşan Temettü Ödemesi

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin